May 8, 2025, 21:26

LUNGevity Mid-Career “Bridge to Breathe” Award

The LUNGevity Foundation is now accepting Letters of Intent for its 2025 Mid-Career “Bridge to Breathe” Research Award, offering $150,000 over two years to support associate-level physician-scientists whose lung cancer clinical research programs require bridge funding while reapplying for major federal or equivalent grants.

Who is eligible?

Applicants must:

Hold the rank of associate professor with tenure (or equivalent)
Demonstrate prior success with NIH R01 (or equivalent) funding
Show strong publication history in lung cancer research
Have submitted a major federal grant application (e.g., NIH R01) within the last 6 months that was not funded
Not hold any concurrent multi-year funding (e.g., NIH, DOD, ACS, institutional startup/retention funds)

Funding at a glance:

$150,000 total ($75,000/year for 2 years)
Research must be clinical and focused on lung cancer
Funded projects must meet annual milestones
Progress and financial reporting is required

Research focus:

This award is intended to sustain clinically relevant lung cancer research at a critical time when other funding may have lapsed. The project must clearly demonstrate clinical impact and feasibility for federal-level resubmission.

Key deadlines:

Full Application Deadline: May 12, 2025 (11:59 PM EDT)
Award Notification: Late Summer 2025
Award Start Date: November 1, 2025

Where to apply:

Submit all materials via ProposalCentral. Only selected applicants will be invited to submit full applications following LOI review.

Contact and details:

Visit www.lungevity.org for full program guidelines and application support.

Bridge to Breathe Award Cancer Research Grants clinical research Lung cancer LUNGevity Foundation mid-career investigators NIH R01 OncoDaily Oncology physician-scientist funding proposalCENTRAL research sustainability translational research

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research

In Memory of Bob Marley: His Battle with Melanoma and the Importance of Early Detection